Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1143.

https://doi.org/10.1182/blood.V128.22.1143.1143

Published: 2016

Journal Articles

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1144.

https://doi.org/10.1182/blood.V128.22.1144.1144

Published: 2016

Journal Articles

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Rakesh Popat, Sarah R Brown, Avie-Lee Tillotson, Fiona Collinson, Louise M Flanagan, Cathy D Williams, Kwee L Yong, Gordon Cook, MD PhD, Matthew W Jenner, MD, Martin Kaiser, Jim Cavet, FRCPath, Dima El-Sharkawi, MD, Chin-Hin Ng, MD MRCP, FRCPATH, Eric Low, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 3321.

https://doi.org/10.1182/blood.V128.22.3321.3321

Published: 2016

Journal Articles

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

Blood (2016) 128 (22): 244.

https://doi.org/10.1182/blood.V128.22.244.244

Published: 2016

Journal Articles

Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience

Sam H Ahmedzai, MBChB BSc FRCP, John A Snowden, MD FRCP, FRCPath, Angela Cox, BA MA PhD, David A Cairns, Cathy D Williams, Anna Hockaday, Jamie Cavenagh, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, Julia Brown, PhD, Curly Morris, MD, Gordon Cook, MD PhD

Blood (2015) 126 (23): 3180.

https://doi.org/10.1182/blood.V126.23.3180.3180

Published: 2015

Journal Articles

Interphase FISH Analysis Of Multiple Myeloma Molecular Risk At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, Christopher Parrish, MD, James D. Cavenagh, MD, John A Snowden, MD, FRCP, FRCPath, Sheila J O'Connor, Roger G Owen, MD, Julia Brown, MB, Treen Morris

Blood (2013) 122 (21): 1884.

https://doi.org/10.1182/blood.V122.21.1884.1884

Published: 2013

Journal Articles

The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Ruth M de Tute, MSc, David A Cairns, PhD, Marie Fletcher, Roger G Owen, MD, Andy Rawstron, PhD, Sheila J.M. O'Connor, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, John A Snowden, MD, FRCP, FRCPath, J. D. Cavenagh, MD, MRCP, Christopher Parrish, MA, MB, BChir, MRCP, Treen Morris, Julia MB Brown, Gordon Cook, MD, PhD

Blood (2013) 122 (21): 3378.

https://doi.org/10.1182/blood.V122.21.3378.3378

Published: 2013

Journal Articles

Identifying An Optimally Effective But Tolerable Dose Of Bendamustine In Combination With Thalidomide and Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma

Stephen A Schey, MD, Kwee L Yong, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, Faith E Davies, MD, Gareth J Morgan, MD PhD, James D. Cavenagh, MD, Gordon Cook, MD, PhD, Mark Cook, Avie-Lee Coney, Sarah Brown, PhD, Louise M Flanagan, PhD, Walter Gregory, PhD, Jim Cavet, FRCPath

Blood (2013) 122 (21): 286.

https://doi.org/10.1182/blood.V122.21.286.286

Published: 2013

Journal Articles

A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, J. D. Cavenagh, MD, MRCP, John A Snowden, MD, FRCP, FRCPath, Christopher Parrish, MD, John Ashcroft, Kwee L Yong, PhD, Jim Cavet, FRCPath, Hannah Hunter, MB, FRCPath, MRCP, Jennifer Bird, Sheila J O'Connor, Julia MB Brown, Treen Morris

Blood (2013) 122 (21): 765.

https://doi.org/10.1182/blood.V122.21.765.765

Published: 2013

Journal Articles

Experience with Long-Term Lenalidomide (LEN) Treatment in the Clinical Setting: Results From the UK Revlimid ® Treatment Continuation Scheme™ (TCS)

Cathy D. Williams, MBBS, MCRP, FRCPath, Mathew Simcock, MSc, Imran Lodhi, MBBS, Suzanne K. Robinson, PhD, Faith E. Davies, MD

Blood (2012) 120 (21): 4067.

https://doi.org/10.1182/blood.V120.21.4067.4067

Published: 2012

Journal Articles

Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.

Blood (2009) 114 (22): 3433.

https://doi.org/10.1182/blood.V114.22.3433.3433

Published: 2009

NARROW

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience

Interphase FISH Analysis Of Multiple Myeloma Molecular Risk At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Identifying An Optimally Effective But Tolerable Dose Of Bendamustine In Combination With Thalidomide and Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma

A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Experience with Long-Term Lenalidomide (LEN) Treatment in the Clinical Setting: Results From the UK Revlimid ® Treatment Continuation Scheme™ (TCS)

Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only